pancreatic ductal carcinoma

Summary

Summary: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.

Top Publications

  1. Mardin W, Mees S. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma?. Ann Surg Oncol. 2009;16:3183-9 pubmed publisher
    ..This article gathers our current knowledge of differentially expressed miRNAs in pancreatic tissues with relevance to PDAC and presents potential diagnostic and therapeutic opportunities...
  2. Nolan Stevaux O, Lau J, Truitt M, Chu G, Hebrok M, Fernandez Zapico M, et al. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009;23:24-36 pubmed publisher
    ....
  3. Inami K, Kajino K, Abe M, Hagiwara Y, Maeda M, Suyama M, et al. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. Oncol Rep. 2008;20:1375-80 pubmed
    ..b>Pancreatic ductal carcinoma remains a fatal disease because its diagnosis often occurs very late...
  4. Schneider G, Kramer O, Fritsche P, Schüler S, Schmid R, Saur D. Targeting histone deacetylases in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2010;14:1255-63 pubmed publisher
    ..Translating these rational-based therapies into the clinic will finally increase our chance to establish an effective HDACI-containing combination therapy effective against PDAC...
  5. Philip P, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009;27:5660-9 pubmed publisher
    ..Patients with either metastatic or locally advanced PDAC must be studied separately...
  6. Han L, Pansare V, Al Abbadi M, Husain M, Feng J. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. Diagn Cytopathol. 2010;38:333-6 pubmed publisher
    ..It appears that the combination of MUC5ac and WT-1 stains is useful in distinguishing pancreatic ductal from ovarian serous carcinoma in body fluid cytology...
  7. De La O J, Emerson L, Goodman J, Froebe S, Illum B, Curtis A, et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A. 2008;105:18907-12 pubmed publisher
    ..At the cellular level, Notch/Kras coactivation promotes rapid reprogramming of acinar cells to a duct-like phenotype, providing an explanation for how a characteristically ductal tumor can arise from nonductal acinar cells...
  8. Fritsche P, Seidler B, Schuler S, Schnieke A, Gottlicher M, Schmid R, et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut. 2009;58:1399-409 pubmed publisher
    ..Although histone deacetylase inhibitors (HDACi) are promising cancer therapeutics regulating proliferation, differentiation and apoptosis, molecular pathways engaged by specific HDAC isoenzymes in cancer are ill defined...
  9. Pine J, Fusai K, Young R, Sharma D, Davidson B, Menon K, et al. Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol. 2009;35:605-10 pubmed publisher
    ..We sought to determine the prognostic importance of serum CRP prior to biliary intervention in the prognosis of pancreatic adenocarcinoma...
  10. Erkan M, Reiser Erkan C, Michalski C, Deucker S, Sauliunaite D, Streit S, et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia. 2009;11:497-508 pubmed
    ..Although both cancer and stellate cells (PSCs) secrete proangiogenic factors, pancreatic cancer is a scirrhous and hypoxic tumor. The impact of cancer-PSCs interactions on angiogenesis was analyzed...

Detail Information

Publications62

  1. Mardin W, Mees S. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma?. Ann Surg Oncol. 2009;16:3183-9 pubmed publisher
    ..This article gathers our current knowledge of differentially expressed miRNAs in pancreatic tissues with relevance to PDAC and presents potential diagnostic and therapeutic opportunities...
  2. Nolan Stevaux O, Lau J, Truitt M, Chu G, Hebrok M, Fernandez Zapico M, et al. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009;23:24-36 pubmed publisher
    ....
  3. Inami K, Kajino K, Abe M, Hagiwara Y, Maeda M, Suyama M, et al. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. Oncol Rep. 2008;20:1375-80 pubmed
    ..b>Pancreatic ductal carcinoma remains a fatal disease because its diagnosis often occurs very late...
  4. Schneider G, Kramer O, Fritsche P, Schüler S, Schmid R, Saur D. Targeting histone deacetylases in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2010;14:1255-63 pubmed publisher
    ..Translating these rational-based therapies into the clinic will finally increase our chance to establish an effective HDACI-containing combination therapy effective against PDAC...
  5. Philip P, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009;27:5660-9 pubmed publisher
    ..Patients with either metastatic or locally advanced PDAC must be studied separately...
  6. Han L, Pansare V, Al Abbadi M, Husain M, Feng J. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. Diagn Cytopathol. 2010;38:333-6 pubmed publisher
    ..It appears that the combination of MUC5ac and WT-1 stains is useful in distinguishing pancreatic ductal from ovarian serous carcinoma in body fluid cytology...
  7. De La O J, Emerson L, Goodman J, Froebe S, Illum B, Curtis A, et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A. 2008;105:18907-12 pubmed publisher
    ..At the cellular level, Notch/Kras coactivation promotes rapid reprogramming of acinar cells to a duct-like phenotype, providing an explanation for how a characteristically ductal tumor can arise from nonductal acinar cells...
  8. Fritsche P, Seidler B, Schuler S, Schnieke A, Gottlicher M, Schmid R, et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut. 2009;58:1399-409 pubmed publisher
    ..Although histone deacetylase inhibitors (HDACi) are promising cancer therapeutics regulating proliferation, differentiation and apoptosis, molecular pathways engaged by specific HDAC isoenzymes in cancer are ill defined...
  9. Pine J, Fusai K, Young R, Sharma D, Davidson B, Menon K, et al. Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol. 2009;35:605-10 pubmed publisher
    ..We sought to determine the prognostic importance of serum CRP prior to biliary intervention in the prognosis of pancreatic adenocarcinoma...
  10. Erkan M, Reiser Erkan C, Michalski C, Deucker S, Sauliunaite D, Streit S, et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia. 2009;11:497-508 pubmed
    ..Although both cancer and stellate cells (PSCs) secrete proangiogenic factors, pancreatic cancer is a scirrhous and hypoxic tumor. The impact of cancer-PSCs interactions on angiogenesis was analyzed...
  11. Yeh J. Prognostic signature for pancreatic cancer: are we close?. Future Oncol. 2009;5:313-21 pubmed publisher
    ..This review will therefore focus on the advantages of a prognostic gene signature for pancreatic cancer, the advances that have been made thus far, the approaches used and the challenges that remain...
  12. Cui Y, Li T, Zhang D, Han J. Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma. Cancer Invest. 2010;28:242-7 pubmed publisher
    ..pEzrin(- Tyr353) may be a potent prognosis predictor for pancreatic cancer...
  13. Taii A, Hamada S, Kataoka K, Yasukawa S, Sonoyama T, Okanoue T, et al. Correlations between p53 gene mutations and histologic characteristics of pancreatic ductal carcinoma. Pancreas. 2009;38:e60-7 pubmed
    ....
  14. Vogler M, Walczak H, Stadel D, Haas T, Genze F, Jovanovic M, et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 2009;69:2425-34 pubmed publisher
    ..These findings build the rationale for further (pre)clinical development of XIAP inhibitors and TRAIL against pancreatic cancer...
  15. Olive K, Jacobetz M, Davidson C, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457-61 pubmed publisher
    ..Thus, inefficient drug delivery may be an important contributor to chemoresistance in pancreatic cancer...
  16. Greither T, Grochola L, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2010;126:73-80 pubmed publisher
    ..Furthermore, the putative target genes for these microRNAs suggest a complex signaling network that can affect PDAC tumorigenesis and tumor progression...
  17. Karanjawala Z, Illei P, Ashfaq R, Infante J, Murphy K, Pandey A, et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol. 2008;32:188-96 pubmed publisher
    ..New markers to distinguish benign reactive glands from infiltrating ductal adenocarcinoma of the pancreas are needed...
  18. Sanlioglu A, Dirice E, Elpek O, Korcum A, Ozdogan M, Suleymanlar I, et al. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Pancreas. 2009;38:154-60 pubmed publisher
    ....
  19. Nishida M, Koito K, Hirokawa N, Hori M, Satoh T, Hareyama M. Does contrast-enhanced ultrasound reveal tumor angiogenesis in pancreatic ductal carcinoma? A prospective study. Ultrasound Med Biol. 2009;35:175-85 pubmed publisher
    ..Twenty-seven subjects with advanced pancreatic ductal carcinoma were treated by chemoradiotherapy...
  20. Pryczynicz A, Guzinska Ustymowicz K, Kemona A, Czyzewska J. Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. Anticancer Res. 2008;28:1399-404 pubmed
    ..Recent reports have indicated that they are also involved in the growth of pancreatic ductal carcinoma, its invasiveness and metastasis.
  21. Golcher H, Brunner T, Grabenbauer G, Merkel S, Papadopoulos T, Hohenberger W, et al. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol. 2008;34:756-64 pubmed publisher
    ..In conclusion a new treatment strategy was developed using multimodality treatment for pancreatic carcinoma deemed to be resectable by CT-scan...
  22. Jones S, Zhang X, Parsons D, Lin J, Leary R, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-6 pubmed publisher
    ..Dysregulation of these core pathways and processes through mutation can explain the major features of pancreatic tumorigenesis...
  23. Koorstra J, Hustinx S, Offerhaus G, Maitra A. Pancreatic carcinogenesis. Pancreatology. 2008;8:110-25 pubmed publisher
    ..This review focuses mainly on the current knowledge about the molecular insights of the pathogenesis of pancreatic ductal adenocarcinoma...
  24. Bachmann J, Heiligensetzer M, Krakowski Roosen H, Buchler M, Friess H, Martignoni M. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg. 2008;12:1193-201 pubmed publisher
    ..Remarkably, there are only a few data available on the impact of cachexia in patients with pancreatic cancer scheduled for tumor resection...
  25. Nielsen S, Møllgård K, Clement C, Veland I, Awan A, Yoder B, et al. Characterization of primary cilia and Hedgehog signaling during development of the human pancreas and in human pancreatic duct cancer cell lines. Dev Dyn. 2008;237:2039-52 pubmed publisher
    ..These findings indicate that primary cilia are involved in pancreatic development and postnatal tissue homeostasis...
  26. Li J, Belogortseva N, Porter D, Park M. Chmp1A functions as a novel tumor suppressor gene in human embryonic kidney and ductal pancreatic tumor cells. Cell Cycle. 2008;7:2886-93 pubmed
    ..Taken together, our data indicates that Chmp1A is a novel tumor suppressor, especially in pancreas and that Chmp1A regulates tumor growth potentially through p53 signaling pathway...
  27. Yantiss R, Cosar E, Fischer A. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol. 2008;52:133-8 pubmed
    ..To evaluate insulin-like growth factor-II mRNA binding protein 3 (IMP3), which is an oncofetal RNA-binding protein expressed in pancreatic carcinomas and detectable by immunohistochemistry, in diagnosis of pancreatic cancer...
  28. Yamazaki M, Nakamura K, Mizukami Y, Ii M, Sasajima J, Sugiyama Y, et al. Sonic hedgehog derived from human pancreatic cancer cells augments angiogenic function of endothelial progenitor cells. Cancer Sci. 2008;99:1131-8 pubmed publisher
    ..Targeting SHH would be a novel therapeutic approach that can inhibit not only proliferation of cancer cells but also EPC-mediated angiogenesis...
  29. Albores Saavedra J, Weimersheimer Sandoval M, Chable Montero F, Montante Montes de Oca D, Hruban R, Henson D. The foamy variant of pancreatic intraepithelial neoplasia. Ann Diagn Pathol. 2008;12:252-9 pubmed publisher
    Foamy gland adenocarcinoma is a variant of pancreatic ductal carcinoma, whose precursor has not been described...
  30. Rautou P, Lévy P, Vullierme M, O Toole D, Couvelard A, Cazals Hatem D, et al. Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study. Clin Gastroenterol Hepatol. 2008;6:807-14 pubmed publisher
    ..The aim of this study was to assess time-related morphologic changes and risk of progress to malignancy in patients with BD IPMN. A prospective design was used in an academic tertiary referral center...
  31. Erkan M, Michalski C, Rieder S, Reiser Erkan C, Abiatari I, Kolb A, et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2008;6:1155-61 pubmed publisher
    ..Pancreatic stellate cells (PSCs) produce this excessively desmoplastic microenvironment. The impact of PSC activity on PDAC behavior in vivo is analyzed...
  32. Herman J, Swartz M, Hsu C, Winter J, Pawlik T, Sugar E, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503-10 pubmed publisher
    ..To examine the efficacy of adjuvant chemoradiotherapy after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PC) in patients undergoing resection at Johns Hopkins Hospital (JHH; Baltimore, MD)...
  33. Hamacher R, Schmid R, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer. 2008;7:64 pubmed publisher
    ....
  34. Reiser Erkan C, Erkan M, Pan Z, Bekasi S, Giese N, Streit S, et al. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2008;7:1352-9 pubmed
    ..Clinically, absence of Pim-1 expression correlates with poor prognosis in prostate cancer. In the present study, the expression of Pim-1 is analyzed in pancreatic cancer and correlated to clinicopathological parameters...
  35. Liau S, Whang E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res. 2008;14:1470-7 pubmed publisher
    ..In this study, we tested the hypothesis that HMGA1 promotes chemoresistance to gemcitabine in pancreatic cancer cells...
  36. Murphy N, Scarlett C, Kench J, Sum E, Segara D, Colvin E, et al. Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. Br J Cancer. 2008;98:537-41 pubmed publisher
    ....
  37. Funel N, Giovannetti E, Del Chiaro M, Mey V, Pollina L, Nannizzi S, et al. Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Lab Invest. 2008;88:773-84 pubmed publisher
    ..The use of these ex vivo techniques for molecular analysis of tumors therefore appears to be of some value in implementing the clinical management of PDAC...
  38. Hoffmann A, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, et al. High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia. 2008;10:674-9 pubmed
    ..In this study, we investigated the prognostic values of HIF1a, bFGF, VEGF, and PDGFA gene expressions as well as their interrelationships...
  39. Guimaraes A, Rakhlin E, Weissleder R, Thayer S. Magnetic resonance imaging monitors physiological changes with antihedgehog therapy in pancreatic adenocarcinoma xenograft model. Pancreas. 2008;37:440-4 pubmed publisher
    ..We tested whether magnetic resonance imaging measures of vascular volume fraction (VVF) using magnetic iron oxide nanoparticles are sensitive to the antiangiogenic effect of targeted Shh therapies in a PDAC xenograft model...
  40. Hristov A, Cope L, Reyes M, Singh M, Iacobuzio Donahue C, Maitra A, et al. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol. 2009;22:43-9 pubmed publisher
    ..Our results support a role for HMGA2 in the progression of pancreatic ductal adenocarcinoma and suggest that it could be a useful biomarker and rational therapeutic target in more advanced disease...
  41. Baiocchi G, Portolani N, Bertagna F, Gheza F, Pizzocaro C, Giubbini R, et al. Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: preliminary results. J Exp Clin Cancer Res. 2008;27:10 pubmed publisher
    ..In conclusion, this preliminary experience suggests that 18FDG-PET may prove useful for malignancy detection in IPMN, improving differential diagnosis with benign intraductal papillary growth by functional data...
  42. Spencer J, Sagartz J, Wold W, Toth K. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Ther. 2009;16:912-22 pubmed publisher
    ..These studies suggest that the SHPC6 cell line may be useful as a model for disseminated pancreatic cancer, and that INGN 007 may be a safe and effective vector to treat these tumors...
  43. Higgins D, Canfield P. Histopathological examination of the pancreas of the Koala (Phascolarctos cinereus). J Comp Pathol. 2009;140:217-24 pubmed publisher
    ..Disorders not previously reported in the pancreas of koalas included the following: inflammation and necrosis; atrophy and fibrosis of exocrine pancreatic tissue; lymphosarcoma; pancreatic heterotopy; and ductal adenocarcinoma...
  44. Hav M, Lem D, Chhut S, Kong R, Pauwels P, Cuvelier C, et al. Clear-cell variant of solid-pseudopapillary neoplasm of the pancreas: a case report and review of the literature. Malays J Pathol. 2009;31:137-41 pubmed
    ..Although a rare neoplasm, it is important to recognize this entity for appropriate management...
  45. Dineen S, Roland C, Greer R, Carbon J, Toombs J, Gupta P, et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res. 2010;70:2852-61 pubmed publisher
    ..The continued development of JP1201 and other strategies designed to enhance therapy-induced apoptosis in pancreatic cancer is warranted...
  46. Barton J, Bois J, Sarr M, Wood C, Qin R, Thomsen K, et al. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg. 2009;13:2050-8 pubmed publisher
    ..Preoperative serum values of CA 19-9 have been reported to be associated with survival in patients undergoing resection of pancreatic adenocarcinoma...
  47. Morton J, Karim S, Graham K, Timpson P, Jamieson N, Athineos D, et al. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology. 2010;139:292-303 pubmed publisher
    ..The aim of this study was to assess the importance of Src in human PDAC and to use a genetically engineered mouse model of PDAC to determine the effects of dasatinib on PDAC progression...
  48. Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, Castagnoli C, et al. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer. 2009;125:639-48 pubmed publisher
    ..It is thus a promising and clinically relevant molecular target candidate for immunotherapeutic approaches as new adjuvants to conventional treatments in pancreatic cancer...
  49. Harikumar K, Kunnumakkara A, Sethi G, Diagaradjane P, Anand P, Pandey M, et al. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer. 2010;127:257-68 pubmed publisher
    ..Overall our results demonstrate that resveratrol can potentiate the effects of gemcitabine through suppression of markers of proliferation, invasion, angiogenesis and metastasis...
  50. Chu C, Mazo A, Sarmiento J, Staley C, Adsay N, Umpierrez G, et al. Impact of diabetes mellitus on perioperative outcomes after resection for pancreatic adenocarcinoma. J Am Coll Surg. 2010;210:463-73 pubmed publisher
    ..Associations between diabetes mellitus (DM) and pancreatic ductal adenocarcinoma (PDAC) are well established; however, the impact of DM on perioperative morbidity and mortality after PDAC resection is unclear...
  51. Hermanova M, Karasek P, Nenutil R, Kyr M, Tomasek J, Baltasova I, et al. Clinicopathological correlations of cyclooxygenase-2, MDM2, and p53 expressions in surgically resectable pancreatic invasive ductal adenocarcinoma. Pancreas. 2009;38:565-71 pubmed publisher
    ..The complex cross talks between p53 and COX-2 and scenarios explaining patterns of p53 and COX-2 expressions in precursor and cancer lesions have been recently reported...
  52. Takahashi H, Ohigashi H, Ishikawa O, Eguchi H, Gotoh K, Yamada T, et al. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg. 2010;251:461-9 pubmed publisher
    ..To evaluate serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy (CRT) for resectable pancreatic cancer (PC) in the earlier identification of patients who are likely to benefit from subsequent resection...
  53. Cao W, Adley B, Liao J, Lin X, Talamonti M, Bentrem D, et al. Mucinous nonneoplastic cyst of the pancreas: apomucin phenotype distinguishes this entity from intraductal papillary mucinous neoplasm. Hum Pathol. 2010;41:513-21 pubmed publisher
    ..For the first time, using HUMARA assay, we demonstrate the nonneoplastic nature of these cysts and further characterize morphologic and immunophenotypic properties that allow differentiation from intraductal papillary mucinous neooplasm...
  54. Meng Y, Lu Z, Yu S, Zhang Q, Ma Y, Chen J. Ezrin promotes invasion and metastasis of pancreatic cancer cells. J Transl Med. 2010;8:61 pubmed publisher
    ..Ezrin plays important roles in cell motility, invasion and tumor progression, and it is especially crucial for metastasis. However, its function in pancreatic cancer remains elusive...
  55. Ringold D, Shah R. Peroral pancreatoscopy in the diagnosis and management of intraductal papillary mucinous neoplasia and indeterminate pancreatic duct pathology. Gastrointest Endosc Clin N Am. 2009;19:601-13 pubmed publisher
    ..Despite recent advances, refinements in endoscope caliber, tip deflection, and optics are still required for more routine application in pancreatic diseases...
  56. Guarise A, Faccioli N, Ferrari M, Salvia R, Mucelli R, Morana G, et al. Evaluation of serial changes of pancreatic branch duct intraductal papillary mucinous neoplasms by follow-up with magnetic resonance imaging. Cancer Imaging. 2008;8:220-8 pubmed publisher
    ..No cystic lesion showed changes in morphology and structure. Branch duct IPMNs smaller than 3 cm, without associated filling defects, tend to be stable, making 'watch and wait' management possible...
  57. Sitek B, Sipos B, Alkatout I, Poschmann G, Stephan C, Schulenborg T, et al. Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. J Proteome Res. 2009;8:1647-56 pubmed publisher
    ....
  58. Abasolo I, Pujal J, Rabanal R, Serafin A, Navarro P, Millán O, et al. FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours. Eur J Nucl Med Mol Imaging. 2009;36:1156-66 pubmed publisher
    ..The aim was to evaluate FDG PET imaging in Ela1-myc mice, a pancreatic cancer model resulting in the development of tumours with either acinar or mixed acinar-ductal phenotype...
  59. Pedicone R, Adham M, Hervieu V, Lombard Bohas C, Guibal A, Scoazec J, et al. Long-term survival after pancreaticoduodenectomy for endocrine tumors of the ampulla of Vater and minor papilla. Pancreas. 2009;38:638-43 pubmed publisher
    ..Endocrine tumors of the ampullary region are rare, and accurate indications for their management are lacking. We aimed to evaluate the outcome of surgical treatment in this indication...
  60. Chipitsyna G, Gong Q, Anandanadesan R, Alnajar A, Batra S, Wittel U, et al. Induction of osteopontin expression by nicotine and cigarette smoke in the pancreas and pancreatic ductal adenocarcinoma cells. Int J Cancer. 2009;125:276-85 pubmed publisher
    ..They provide the first insight into a nicotine-initiated signal transduction pathway that regulates OPN as a possible tumorigenic mechanism in PDA...
  61. Mukherjee P, Basu G, Tinder T, Subramani D, Bradley J, Arefayene M, et al. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol. 2009;182:216-24 pubmed
    ..The preclinical data provide the rationale to design clinical trials with a combination of MUC1-based vaccine, celecoxib, and gemcitabine for the treatment of pancreatic cancer...
  62. Shen X, Mailey B, Ellenhorn J, Chu P, Lowy A, Kim J. CC chemokine receptor 9 enhances proliferation in pancreatic intraepithelial neoplasia and pancreatic cancer cells. J Gastrointest Surg. 2009;13:1955-62; discussion 1962 pubmed publisher
    ..There are little data, however, regarding their role in premalignant lesions. Our objective was to determine the role of CC chemokine receptor 9 (CCR9) in pancreatic intraepithelial neoplasia (PanIN)...